Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)</li></ul>

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

LNTH: Evergreen Acquisition Promotes Future Innovation

Global Healthcare Analyst

Tina Banerjee

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.</li>
<li>The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.</li>
<li>Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. </li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.
The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.
Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. 


Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

<ul><li>Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.</li><li>It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.</li><li>The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.</li></ul>

Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.

LNTH: Initiating Coverage - A Glowing Recommendation

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> announced that two participants have been dosed with 64Cu-SAR-bisPSMA and imaged days after the commencement of the Co-PSMA Investigator-Initiated Trial (IIT).</li>
<li>SARTATE completes final assessment in Phase II diagnostic trial for neuroendocrine tumours. SAR-Bombesin began trial for castrate resistant prostate cancer.</li>
<li>Clarity’s copper platform, strong prostate pipeline, and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.</li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) announced that two participants have been dosed with 64Cu-SAR-bisPSMA and imaged days after the commencement of the Co-PSMA Investigator-Initiated Trial (IIT).
SARTATE completes final assessment in Phase II diagnostic trial for neuroendocrine tumours. SAR-Bombesin began trial for castrate resistant prostate cancer.
Clarity’s copper platform, strong prostate pipeline, and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology and other indications.


Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore

United States

Lantheus Holdings, Inc. develops, manufactures, sells, and distributes diagnostic medical imaging agents and products. The Company offers imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. Lantheus Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lantheus Holdings (LNTH US)

LNTH: Evergreen Acquisition Promotes Future Innovation

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

LNTH: LMI Acquisition and NeuraCeq

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

LNTH: Initiating Coverage - A Glowing Recommendation

Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics. It offers a portfolio of diagnostic &...

Zacks Small Cap Research

Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore

Clarity Pharmaceuticals doses participants with its lead candidate 64Cu-SAR-bisPSMA and completed final assessment in Phase 2 trial of another...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

LNTH: Evergreen Acquisition Promotes Future Innovation

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

LNTH: LMI Acquisition and NeuraCeq

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

​Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

LNTH: Initiating Coverage - A Glowing Recommendation

Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics. It offers a portfolio of diagnostic &...

Zacks Small Cap Research

Clarity Pharmaceuticals (CU6 AU): Well-Funded, Pipeline Progressing Well, Growth Prospects Galore

​Clarity Pharmaceuticals doses participants with its lead candidate 64Cu-SAR-bisPSMA and completed final assessment in Phase 2 trial of another...

Tina Banerjee

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Clarity Pharmaceuticals doses participants with its lead candidate 64Cu-SAR-bisPSMA and completed final assessment in Phase 2 trial of another...